Genomatica Extends Research Agreement With Dow Chemical
For Next Generation Microbial Expression Technology using SimPheny(TM)
San Diego. Genomatica, Inc., a leading systems biology company, announced that it has extended its research agreement with The Dow Chemical Company after successfully achieving a series of scientific milestones. Under the terms of the extended agreement, Genomatica will apply its modeling and simulation technology to assist Dow in improving recombinant protein Expression from specially designed strains of Pseudomonas fluorescens. Dow will license Genomatica's systems biology and modeling platform, SimPheny(TM), to expand their capabilities to improve and develop the next generation of microbial expression systems for the production of proteins. Using its model-driven research methodologies, scientists at Genomatica will be identifying solutions for improving protein production and fermentation processes.
"We are excited to continue our relationship with Dow, a company committed to using leading technology to provide innovative biological products and solutions to their customers worldwide," commented Christophe H. Schilling, Ph.D., Vice President and Chief Technology Officer for Genomatica. "Our research efforts in the first year of our collaboration have demonstrated the effectiveness of our modeling technology for applications in microbial protein production. Moreover, it has set the stage for a broader implementation of our model-driven research methodologies to improve fermentation processes and protein expression."
"We had a very fruitful collaboration with Genomatica last year," said Mani Subramanian, Dow's Global Leader of Biotechnology and Bioprocessing Research and Development. "The capability to model metabolic pathways and their action will allow us to design strains in silico with improved properties. This will save time and result in more robust strains and bioprocesses," said Subramanian.
Other news from the department
